Imara Announces Pricing of Public Offering
July 13, 2021 22:58 ET
|
Imara, Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
Imara Announces Launch of Proposed Public Offering
July 13, 2021 16:01 ET
|
Imara, Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors
June 30, 2021 07:00 ET
|
Imara, Inc.
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 11, 2021 03:00 ET
|
Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 04, 2021 07:00 ET
|
Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 07:00 ET
|
Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 04, 2021 07:00 ET
|
Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Sickle Cell Disease Treatment Market to Exhibit a CAGR of 18.5% and Reach USD 7.71 Billion by 2027; FDA Approval for Emmaus’s Endari to Aid Development, states Fortune Business Insights™
January 20, 2021 08:56 ET
|
Fortune Business Insights
Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global sickle cell disease treatment market size is expected to reach USD 7.71 billion in 2027, exhibiting a CAGR of 18.5% during the forecast...
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
November 17, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
New Research Reveals Gazelle Diagnostic Device Outperformed Rapid Diagnostic Test for P. Vivax Malaria, Detected Challenging Types of Malaria, and Provided Affordable Sickle Cell Disease Detection
November 16, 2020 16:10 ET
|
Hemex Health
PORTLAND, Ore., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Hemex Health, an innovator in point-of-care diagnostic technologies, announced today that researchers will present five scientific posters at the...